In a significant portfolio shift, Farallon Capital Management fully exited its position in TYRA Biosciences (TYRA), a clinical-stage biotech company. According to regulatory filings for the second quarter of 2026, the firm sold its entire stake of 3.58 million shares, which had been valued at approximately $137.15 million.
This disclosure comes from a mandatory quarterly 13F report, which reveals positions held as of June 30, 2026, and was filed on August 14. These filings have a significant delay, so the trades occurred at an unknown time during the second quarter. TYRA is focused on developing precision medicines for cancer and recently reported progress in its Phase 2 clinical trials, with initial data for one study expected in September 2026. [1, 3]